DESCRIPTION CONCERTA® is a central nervous system (CNS) stimulant. CONCERTA® is available in four tablet strengths. Each extended-release tablet for once-a-day oral administration contains 18, 27, 36, or 54 mg of methylphenidate HCl USP and is designed to have a 12-hour duration of effect. Chemically, methylphenidate HCl is d,l (racemic) methyl α-phenyl-2-piperidineacetate hydrochloride. CONCERTA® is a central nervous system (CNS) stimulant. CONCERTA is available in four strengths. Each extended-release tablet for oral administration contains 18, 27, 36, or 54 mg of. Concerta (Methylphenidate Extended-Release Tablets) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications including drug comparison and health resources. Learn about methylphenidate ER usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular alternatives. Find patient medical information for Methylphenidate (Concerta, Ritalin, and others) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings Concerta (methylphenidate) is a prescription extended-release oral tablet that treats ADHD in adults and children]. Learn about dosage, side effects, and more. Are methylphenidate er and Concerta the same? Find out the crucial differences in formulation, release mechanisms, and therapeutic effects between the brand-name and generic versions. Concerta is used to treat attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD). Learn about side effects, interactions and indications. Methylphenidate ER vs. Concerta: Key Differences Concerta is a specific brand of methylphenidate extended-release that uses a unique 12-hour osmotic pump delivery system (OROS), making it distinct from other methylphenidate ER formulations that typically provide only 8 hours of coverage. 1 Fact Sheet Methylphenidate ER (Concerta, Ritalin SR and LA, others) Fact Sheet [G] for General Psychiatry November 18, 2025 Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP.